Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.

XB130 is a newly characterized adaptor protein that was reported to promote thyroid tumor growth, but its role in the progression of other kinds of cancer such as gastric cancer (GC) remains unknown. Accordingly, we investigated the association between XB130 expression and the prognosis of GC patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Min Shi, Weizhen Huang, Li Lin, Dayong Zheng, Qiang Zuo, Lin Wang, Nina Wang, Yajun Wu, Yulin Liao, Wangjun Liao
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bc6c3a812eb9423a8ba4f290e6e5c9c0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc6c3a812eb9423a8ba4f290e6e5c9c0
record_format	dspace
spelling	oai:doaj.org-article:bc6c3a812eb9423a8ba4f290e6e5c9c02021-11-18T07:07:53ZSilencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.1932-620310.1371/journal.pone.0041660https://doaj.org/article/bc6c3a812eb9423a8ba4f290e6e5c9c02012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22927913/?tool=EBIhttps://doaj.org/toc/1932-6203XB130 is a newly characterized adaptor protein that was reported to promote thyroid tumor growth, but its role in the progression of other kinds of cancer such as gastric cancer (GC) remains unknown. Accordingly, we investigated the association between XB130 expression and the prognosis of GC patients. The subjects were 411 patients with GC in stages I to IV. XB130 expression was examined in surgical specimens of GC. Kaplan-Meier analysis and the Cox proportional hazards model were used to assess the prognostic significance of XB130 for survival and recurrence. Moreover, GC cells stably transfected with XB130 short hairpin RNA were established to analyze the effect of XB130 on sensitivity of chemotherapy. The results show that both XB130 mRNA and protein expression were detectable in normal gastric tissues. The overall survival time of stage IV patients and the disease-free period after radical resection of GC in stage I-III patients were significantly shorter when immunohistochemical staining for XB130 was low than when staining was high (both p<0.05). XB130 expression also predicted tumor sensitivity to several chemotherapy agents. Viability of both XB130-silenced SGC7901 cells and wild-type cells was suppressed by 5-fluorouracil (5-FU), cisplatin, and irinotecan in a dose-dependent way, but cisplatin and irinotecan were more sensitive against sXB130-silenced GC cells and 5-FU showed higher sensitivity to wild-type cells. When treated by 5-FU, patients with high expression of XB130 tumors had a higher survival rate than those with low expression tumors. These findings indicate that reduced XB130 protein expression is a prognostic biomarker for shorter survival and a higher recurrence rate in patients with GC, as well as for the response to chemotherapy.Min ShiWeizhen HuangLi LinDayong ZhengQiang ZuoLin WangNina WangYajun WuYulin LiaoWangjun LiaoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 8, p e41660 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Min Shi Weizhen Huang Li Lin Dayong Zheng Qiang Zuo Lin Wang Nina Wang Yajun Wu Yulin Liao Wangjun Liao Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
description	XB130 is a newly characterized adaptor protein that was reported to promote thyroid tumor growth, but its role in the progression of other kinds of cancer such as gastric cancer (GC) remains unknown. Accordingly, we investigated the association between XB130 expression and the prognosis of GC patients. The subjects were 411 patients with GC in stages I to IV. XB130 expression was examined in surgical specimens of GC. Kaplan-Meier analysis and the Cox proportional hazards model were used to assess the prognostic significance of XB130 for survival and recurrence. Moreover, GC cells stably transfected with XB130 short hairpin RNA were established to analyze the effect of XB130 on sensitivity of chemotherapy. The results show that both XB130 mRNA and protein expression were detectable in normal gastric tissues. The overall survival time of stage IV patients and the disease-free period after radical resection of GC in stage I-III patients were significantly shorter when immunohistochemical staining for XB130 was low than when staining was high (both p<0.05). XB130 expression also predicted tumor sensitivity to several chemotherapy agents. Viability of both XB130-silenced SGC7901 cells and wild-type cells was suppressed by 5-fluorouracil (5-FU), cisplatin, and irinotecan in a dose-dependent way, but cisplatin and irinotecan were more sensitive against sXB130-silenced GC cells and 5-FU showed higher sensitivity to wild-type cells. When treated by 5-FU, patients with high expression of XB130 tumors had a higher survival rate than those with low expression tumors. These findings indicate that reduced XB130 protein expression is a prognostic biomarker for shorter survival and a higher recurrence rate in patients with GC, as well as for the response to chemotherapy.
format	article
author	Min Shi Weizhen Huang Li Lin Dayong Zheng Qiang Zuo Lin Wang Nina Wang Yajun Wu Yulin Liao Wangjun Liao
author_facet	Min Shi Weizhen Huang Li Lin Dayong Zheng Qiang Zuo Lin Wang Nina Wang Yajun Wu Yulin Liao Wangjun Liao
author_sort	Min Shi
title	Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_short	Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_full	Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_fullStr	Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_full_unstemmed	Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_sort	silencing of xb130 is associated with both the prognosis and chemosensitivity of gastric cancer.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/bc6c3a812eb9423a8ba4f290e6e5c9c0
work_keys_str_mv	AT minshi silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT weizhenhuang silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT lilin silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT dayongzheng silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT qiangzuo silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT linwang silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT ninawang silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT yajunwu silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT yulinliao silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer AT wangjunliao silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
_version_	1718423939045130240

Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.

Ejemplares similares